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Abstract
Background: Drug resistance and disease progression are still the major obstacles in the treatment of chronic
myeloid leukemia (CML). Increasing researches have demonstrated that autophagy becomes activated when
cancer cells are subjected to chemotherapy, which is involved in the development of drug resistance. Therefore,
combining chemotherapy with inhibition of autophagy serves as a new strategy in cancer treatment. Tigecycline
is an antibiotic that has received attention as an anti-cancer agent due to its inhibitory effect on mitochondrial
translation. However, whether combination of tigecycline with inhibition of autophagy could overcome drug
resistance in CML remains unclear.
Methods: We analyzed the biological and metabolic effect of tigecycline on CML primary cells and cell lines to
investigate whether tigecycline could regulate autophagy in CML cells and whether coupling autophagy inhibition
with treatment using tigecycline could affect the viabilities of drug-sensitive and drug-resistant CML cells.
Results: Tigecycline inhibited the viabilities of CML primary cells and cell lines, including those that were drug-
resistant. This occurred via the inhibition of mitochondrial biogenesis and the perturbation of cell metabolism,
which resulted in apoptosis. Moreover, tigecycline induced autophagy by downregulating the PI3K-AKT-mTOR
pathway. Additionally, combining tigecycline use with autophagy inhibition further promoted the anti-leukemic
activity of tigecycline. We also observed that the anti-leukemic effect of tigecycline is selective. This is because
the drug targeted leukemic cells but not normal cells, which is because of the differences in the mitochondrial
biogenesis and metabolic characterization between the two cell types.
Conclusions: Combining tigecycline use with autophagy inhibition is a promising approach for overcoming drug
resistance in CML treatment.
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Background
Chronic myeloid leukemia (CML) is a myeloproliferative
neoplasm companied with the BCR-ABL fusion gene,
which is encoded by the Philadelphia chromosome [1].
The BCR-ABL fusion protein plays a key role in CML
leukemogenesis by activating its downstream signaling
pathway of survival and proliferation [2, 3]. Imatinib is a
targeted competitive inhibitor of BCR-ABL tyrosine kin-
ase that has changed the clinical treatment and progno-
sis of CML. Other tyrosine kinase inhibitors (TKIs) such
as dasatinib and nilotinib have a higher anti-leukemic
activity and are associated with fewer side effects.
However, acquired resistance to TKIs is one of the main
obstacles to effective CML treatment and is involved in
gene amplification of ABL tyrosine kinase point muta-
tions [4]. Patients with these ABL tyrosine kinase point
mutations generally have a poor prognosis and a higher
mortality rate.
The survival, proliferation and drug resistance prop-
erty of leukemic cells are mainly dependent on their
crosstalk with the bone marrow microenvironment [5].
In addition, hypoxia and nutrient deficiency are charac-
teristics of the microenvironments of cancers [6]. Under
such hostile surroundings, leukemic cells adapt dynam-
ically by adjusting their metabolic phenotype. In order to
maintain the energy balance between ATP production and
the need for excessive proliferation and survival, cancer
cells develop a novel metabolic phenotype that is more
dependent on glycolysis than on mitochondrial oxidative
phosphorylation (OXPHOS). This phenomenon is known
as Warburg effect [7]. In contrast, some researches have
recently demonstrated that mitochondrial respiration still
plays a vital role in the metabolic properties of cancer cells
by reinforcing mitochondrial activity [8, 9]. In tumorigen-
esis, mitochondria are not only biosynthetic organelles
involved in bioenergetic reactions, but they are also
survival signaling mediators for the cancer cells. There-
fore, understanding and targeting the mechanisms under-
lying mitochondrial function would be critical exploitable
points in the development of cancer therapies.
Autophagy can be induced when cancer cells subjected
to hypoxia, poor nutritional conditions and chemotherapy
to allow cancer cells adapt to the developmental micro-
environment [10, 11]. Inhibition of tyrosine kinase by TKIs
not only results in cell death but also causes the induction
of autophagy in CML cells. Importantly, inhibition of
autophagy by pharmacological inhibitors (chloroquine and
bafilomycin A) or knockdown of the autophagy genes
ATG5 and ATG7 in CML cells could potentiate TKIs-
induced cell apoptosis in CML cells [12]. These researches
demonstrated that inhibition of autophagy could improve
the treatment efficiency of TKIs and combining of autoph-
agy inhibition with other anti-cancer drug may be more
efficient treatment to CML cells. Currently, it has been
shown that the antibiotic tigecycline has an interesting
“side effect” of inhibiting mitochondrial translation in can-
cer cells, which results in the killing of cancer cells, as well
as cancer stem cells [13]. The observations challenged the
traditional concept that cancer treating like an infectious
disease with less toxicity. Based on this premise, we hy-
pothesized that tigecycline could be used as an anticancer
drug, as it induces significant apoptosis of CML cells com-
panied with autophagy. Moreover, inhibition of autophagy
could enhance the anti-leukemic effect of tigecycline and
reverse drug resistance to TKI therapy which mainly
attributable to ABL tyrosine kinase point mutations.
Methods
Cell lines and cultures
BCR-ABL positive KBM5 cells and K562 cells were used
as imatinib-sensitive cell lines. On the other hand,
KBM5 cells with T315I mutation (KBM5-STI cells),
which were provided by Prof. Michael Andreeff (Section
of Molecular Hematology and Therapy, Department of
Leukemia, The University of Texas M.D. Anderson
Cancer Center, Houston, TX, USA), were used as an
imatinib-resistant cell line. Thirteen primary CML cells
were obtained from eight newly diagnosed patients
(cases at chronic phase without any mutations) and five
refractory patients (2 cases with T315I mutation, 3 cases
without any mutations) after obtaining written informed
consent. Eight healthy donors were selected by matching
their ages and sex to those of the CML patients. The
study was approved by the Institutional Review Board of
Nanfang Hospital (Guangzhou, China).
Cell viability assay
Cell viability assay was performed using Cell Counting
Kit-8 (CCK8; CK40; Dojingdo, Kumamoto, Japan). Cells
were seeded in 96-well plates and then exposed to
tigecycline (Hisun Pharmaceutical Company, Fuyang,
China) and/or chloroquine (CQ) (14774; Cell Signaling
Technology, Danvers, MA) at the indicated concentra-
tions for 48 h. The cells were incubated with CCK-8
solution for 2 h, after which absorbance was measured
at 450 nm using a SpectraMax Plus microplate reader
(Molecular Devices, Sunnyvale, CA, USA).
Flow cytometry analysis
After stimulation with tigecycline and/or CQ, the cells
were subjected to flow cytometry experiments. An
annexin V-FITC and PI apoptosis detection kit (AD10,
Dojingdo) was used for apoptosis assay according to
the manufacturer’s instructions. A mitochondrial
membrane potential assay kit (12664, Cell Signaling
Technology, Danvers, MA, USA) was used to detect
mitochondrial membrane potential in the CML cells
using the fluorescent dye JC-1.When JC-1 permeates
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into intact mitochondria, it aggregates to orange-red
fluorescence. However, JC-1 infiltrates into impaired mito-
chondria, the dye changed into green fluorescence. The
relative ratio of the green/red fluorescence is therefore used
as an indicator of mitochondrial membrane potential. The
generation of reaction oxygen species (ROS) was monitored
after the cells were stained with a fluorometric dye using a
Fluorometric Intracellular ROS Kit (MAK142; Sigma-
Aldrich, St. Louis, MO, USA) according to the manufac-
turer’s instructions. Furthermore, mitochondrial mass was
measured using Mito Green Probe (KGMP0072, Keygen
Biotech, Nanjing, China) after incubating the cells at 37 °C
for 30 min. All the assays mentioned above were digitized
using a FACSCalibur flow cytometer (Becton-Dickinson,
Franklin Lakes, NJ, USA).
Measurement of oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR)
OCR and ECAR were measured using Seahorse XF24
Flux Analyzer (Seahorse Bioscience, Shanghai, China).
Briefly, the cells were plated on XF24 cell culture plates
coated with Cell-Tak solution (1 mg/mL; MAP-O4012;
ACRO Biosystems, Newark, DE, USA). K562, KBM5,
and KBM5-STI cells were seeded at 250,000 cells/well,
300,000 cells/well, and 300,000 cells/well, respectively,
whereas primary CML cells were plated at 300,000 cells/
well. The cells were seeded in each well in 100 μL of XF
Assay Medium (102353–100, Seahorse Bioscience)
supplemented with 1 mM pyruvate, 2 mM glutamine,
and 10 M glucose for OCR analysis, or 1 mM glutamine
for ECAR measurement. Cell Mito Stress Test Kit
(103015–100, Seahorse Bioscience) and Glycolysis Stress
Test Kit (103020–100, Seahorse Bioscience), which
contained the relevant compounds for each assay, were
used to measure OCR and ECAR, respectively. Oligomy-
cin, carbonyl cyanide 4-(trifluoromethoxy)phenylhydra-
zone (FCCP), and a mixture of rotenone and antimycin
A were used for the OCR analysis, whereas glucose,
oligomycin, and 2-deoxyglucose (2-DG) were used for
the ECAR analysis. The compounds were serially
injected into the cells to measure mitochondrial respir-
ation and glycolysis function, respectively.
Western blotting
Western blotting was performed as before [8]. Briefly,
proteins were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE), transferred to
nitrocellulose membranes, and sequentially incubated
overnight with primary antibodies at 4 °C. After incubation
with secondary antibodies, signals were visualized
using a chemiluminescent detection reagent (WBKLS0500;
Millipore, Billerica, MA, USA). Before the analysis of
cytochrome c, the cytosolic and mitochondrial sub-cellular
fractions needed were separated using a mitochondria
isolation kit (C3601; Beyotime Biotechnology, Shanghai,
China). The western blotting analysis was conducted using
the following primary antibodies: anti-cytochrome c
(11940), anti-cleaved-caspase-9 (32539), anti-cleaved-
caspase-3 (13847), anti-LC3B (51520), and anti-p62
(91526), which were obtained from Abcam (Cambridge,
UK); and p-AKT (Ser473, 4060), p-AKT (Thr308, 13038),
AKT (9272), p-mTOR (Ser2448, 5536), p-P70S6K
(Thr389, 9234), p-4E-BP1 (Thr37/46, 2855), and anti-
ATG5 (12994), which were obtained from Cell Signaling
Technology; and anti-Cox-1(19998), anti-Cox-2(19999)
and anti-Cox-4 (69359), which were obtained from Santa
Cruz Biotechnology (California, USA).
Fluorescence and confocal microscopy
After treatment with tigecycline, CQ, or 3-methyladenine
(3-MA) (9281, Sigma-Aldrich), the CML cells were pre-
pared for the autophagy detection experiment. An autoph-
agy detection kit (139484, Abcam) was optimized and used
for the detection of autophagy in the CML cells by flu-
orescent scanning confocal microscopy (Olympus FV10i;
Olympus, Tokyo, Japan).
Transmission electron microscopy
The cells were stained with uranyl acetate and lead citrate
on a microtome (Leica Ultracut; Leica, Wetzlar, Germany)
and examined with a transmission electron microscope
(Hitachi H-7650; Hitachi, Tokyo, Japan) at an accelerating
voltage of 60 KV. Micrographs were taken at × 7,000 or ×
20,000 magnification.
Quantitative PCR (QPCR)
Mitochondrial DNAs (mtDNAs) were extracted from the
fresh bone marrow mononuclear cells obtained from the
CML patients and healthy donors and stored at −20 °C
until use. Relative mtDNA copy number and the mRNA
levels of Cox-1, Cox-2 and Cox-4 were determined by
qPCR method. The primer sequences used were as fol-
lows: forward primer (Cox-1-F) 5’-CTATACCTATTA
TTCGGCGCATGA-3’and reverse primer (Cox-1-R) 5’-
CAGCTCGGCTCGAATAAGGA-3’ for Cox-1; forward
primer (Cox-2-F) 5’- CTGAACCTACGAGTACACCG-3’
and reverse primer (Cox-2-R) 5’- TTAATTCTAGGAC
GATGGGC-3’ for Cox-2; forward primer (Cox-4-F) 5’-
GCCATGTTCTTCATCGGTTTC-3’ and reverse primer
(Cox-4-R) 5’- GGCCGTACACATAGTGCTTCTG-3’ for
Cox-4; forward primer (18 s-F) 5’- AGGAATTGACG
GAAGGGCAC-3’ and reverse primer (18 s-R) 5’- GG
ACATCTAAGGGCATCACA-3’for 18S; forward primer
(ND1-F) 5’-CCC TAA AAC CCG CCA CAT CT-3’ and
reverse primer (ND1-R) 5’-GAG CGA TGG TGA GAG
CTA AGG T-3’ for ND1; and forward primer (human
globulin (HGB)-F) 5’-GTG CAC CTG ACT CCT GAG G
AG A-3’ and reverse primer (HGB-R) 5’-CCT TGA TAC
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CAA CCT GCC CAG-3’ for HGB. QPCR reactions were
performed on an ABI Prism 7900 sequence detection
system (Applied Biosystems, Foster City, CA). The
relative abundance of a transcript was represented by
the threshold cycle of amplification (CT). The com-
parative CT method was calculated per the manufac-
turer's instructions. The expression level of Cox-1
relative to the baseline level was calculated as 2–ΔC T
(Cox-1),
where ΔCT is (average Cox-1 CT – average 18 s CT) and
is CT (average CT -treated sample – average CT -
untreated sample. The calculation methods of expres-
sion levels of Cox-2, Cox-4 and ND1 are the same as
that of Cox-1. For the calculation method of expres-
sion level of ND1, the reference one is HGB.
Small interfering RNA transfection
Cells were transfected with siRNA (ATG5-F, 5’ CAACTT
GTTTCACGCTATATCAGG; ATG5-R, 5’ CACTTTGT
CAGTTACCAACGTCA) designed by Guangzhou Land
Bio Co. Ltd. (Guangzhou, China) using Lipofectamine®
2000 Transfection Reagent (11668; Invitrogen, Carlsbad,
CA, USA) according the manufacturer’s instructions.
Statistical analysis
GraphPad Prism 5 (GraphPad Software Inc., San Diego,
CA, USA) was used to perform statistical analysis. The
results have been expressed as mean ± standard devia-
tions. Test of comparison between two groups were done
using Student’s t-test (two tailed) and comparisons
between multiple groups were done by one-way ANOVA.
P values < 0.05 were considered statistically significant.
Results
Tigecycline reduced the viabilities of the primary CML
cells and cell lines
Initially, we determined whether tigecycline could inhibit
the viability of CML cells. We chose K562 and KBM5 cell
lines as imatinib-sensitive phenotypes, while KBM5 cells
with T315I mutations (KBM5-STI cells) were the imatinib-
resistant genotype. The cells were similarly treated with
increasing concentrations of tigecycline (6.25–100 μM) for
48 h. The half maximal inhibitory concentration (IC50) of
tigecycline ranged from 51.40 to 86.07 μM against the three
leukemia cell lines (Fig. 1a). Therefore, in order to
standardize the experimental conditions, we used tig-
ecycline at a concentration of 50 μM in subsequent
Fig. 1 Tigecycline inhibits the proliferation of CML cells in dose- and time-dependent manners. (a, c) Viabilities of CML cell lines (K562, KBM5, and
KBM5-STI) after treatment with different concentrations of tigecycline treatment in different time points. (b, d) Proliferations of primary CML cells
obtained from newly diagnosed CML patients and refractory CML patients after treatment with different concentrations of tigecycline in different
time points. Error Bars: SD of 3 independent experiments;* P < 0.05, **P < 0.01, ***P < 0.001
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experiments. It was noted that the inhibitory action of tige-
cycline was dose- and time-dependent and occurred irre-
spective of the cytogenetic mutation status of the cells
(Fig. 1a, c). Moreover, the inhibitory effects of tigecycline
were equally observed in primary CML cells obtained from
the different patients (Fig. 1b, d).
Tigecycline inhibited mitochondrial biogenesis in the CML
cells
Molecular disruption of mitochondrial biogenesis or
OXPHOS could be the target of tigecycline [13]. To
understand the mechanism underlying the anti-leukemic
effect of tigecycline, mitochondrial function experiments
were performed. In the first set of experiments, we mea-
sured the levels of cytochrome c oxidase-1, 2, and 4
(Cox-1, 2, and 4) by western blotting and quantitative
polymerase chain reaction (qPCR) after tigecycline treat-
ment. Mitochondria have an independent genome encod-
ing system that is responsible for two rRNAs, 22 t-RNAs,
and 13 of the 90 proteins in the mitochondrial respiratory
chain [14]. Cox-1 and Cox-2 are the representative mito-
chondrial encode proteins, while Cox-4 is encoded by a
nuclear genome [15]. After tigecycline stimulation, our
data showed that Cox-1 and Cox-2 protein levels signifi-
cantly decreased as compared to that of Cox-4 (Fig. 2a).
However, reductions in Cox-1 and Cox-2 protein levels
did not result in reductions in their respective mRNA
levels in the same cells (Fig. 2b). In addition, these changes
were observed in the primary CML samples (Fig. 2a, b).
This suggests that the anti-leukemic activity of tigecycline
is implicated in the inhibition of mitochondrial protein
translation.
Many important proteins in the mitochondrial respira-
tory chain are encoded by the mitochondrial genome.
Mitochondrial membrane potential, which is the strong
electrochemical proton gradient across the inner mem-
brane, is generated by the mitochondrial respiratory
chain. Here, a sensitive cationic and lipophilic JC-10
fluorescent probe was used to monitor mitochondrial
membrane potential changes in the cells based on the
presence of the JC-10 dye. In the flow cytometry analysis,
the mitochondrial membrane potentials of the cell lines
and primary CML cells began to decrease at different
degree after 24 h of stimulation with tigecycline as the
effect of the mitochondrial membrane potential dis-
ruptor carbonyl cyanide 3-chlorophenylhydrazone (CCCP)
(Fig. 2c). These data indicate that mitochondrial mem-
brane depolarization precedes loss of viability in leukemic
cells exposed to tigecycline.
Mitochondria are the factory of energy supply where
ATP is synthesized. It has equally important roles such
as reactive oxygen species (ROS) production. To investi-
gate the involvement of oxidative stress in tigecycline-
induced mitochondrial impairment, intracellular ROS
levels were measured. Surprisingly, tigecycline did not
cause an increase in ROS levels in any of the cell lines and
patient samples during the treatment period (Fig. 2d). We
postulated that tigecycline produced inhibitory effects
possibly through a novel mechanism that is distinct from
the inhibition of mitochondrial function.
Tigecycline suppressed mitochondrial stress and
glycolysis levels in the CML cells
Damaged mitochondria generate excessive amounts of
harmful substances, which lead to disturbance of mito-
chondrial bioenergy homeostasis and eventually pro-
grammed cell death [16]. Therefore, we monitored the
levels of two main cellular ATP generation mechanisms,
mitochondrial respiration and glycolysis, in the context
of tigecycline strong stimulation. In the real-time assay,
we measured the levels of mitochondrial stress and gly-
colysis and reported them as oxygen consumption rate
(OCR) and extracellular acidification rate (ECAR), re-
spectively. As illustrated in Fig. 3a, there was a signifi-
cant decrease in baseline OCR in the tigecycline-treated
cells. In the presence of tigecycline, the ATP synthase in-
hibitor oligomycin decreased OCR markedly. However,
after stimulation with carbonyl cyanide-4-(trifluoro-
methoxy) phenylhydrazone (FCCP), the OCR of the
tigecycline-treated cells did not increase to the peak
value like that of the control cells did. Moreover, the
tigecycline-treated cells were sensitive to the inhibitory
effect of antimucin A/rotenone (A/R) in the OCR assay.
In addition, the OCR values of the tigecycline-treated
cell lines were significantly lower than those of the
control cells were. Furthermore, we observed that the
glycolysis level in the control cells, as measured in the
ECAR assay, increased due to the serial addition of
glucose and oligomycin to the culture medium. How-
ever, this increase in glycolysis was prevented by 2-
deoxy-D-glucose (2-DG), which is a glycolysis inhibitor.
We however noted that the abovementioned changes
were unremarkable in the presence of tigecycline. In
addition, ECAR decreased significantly in the tigecycline-
treated cells (Fig. 3b). These data demonstrate that tige-
cycline has strong inhibitory effects on mitochondrial
respiration and glycolysis capacity, which are processes in
mitochondrial bioenergy homeostasis.
Tigecycline caused apoptosis of the CML cells by
activating the cytochrome c/caspase-9/caspase-3 pathway
Mitochondrial membrane depolarization and accumula-
tion of ROS are features of apoptosis. Flow cytometry
using Annexin V combined with PI was used to assay
the apoptotic effect of tigecycline on the CML cell lines.
Apoptosis was only slightly observed in the KBM5 cells
after 24 h of treatment with tigecycline; however, no
apoptosis was observed in the K562 and KBM5-STI
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cells, and the effects enlarged significantly after 48 h of
exposure to the drug in all the cell lines (Fig. 4a). When
apoptosis is initiated, cytochrome c, which is a pro-
apoptotic protein and part of the respiratory chain, is
released from the mitochondrial inner membrane into the
cytoplasm to trigger apoptosome formation. This results
Fig. 2 Tigecycline suppresses mitochondrial biogenesis in CML cell lines and primary cells. (a) Effects of increasing concentrations of tigecycline on the
protein levels of cytochrome c oxidase (Cox)-1, Cox-2, and Cox-4 in CML cell lines and primary cells. Tubulin was used as the reference protein in the
western blotting. All the cells were cultured with tigecycline for 48 h before the experiments were conducted. (b) The relative mRNA levels of Cox-1, Cox-2,
and Cox-4 in CML cells after treatment with tigecycline. (c) Evaluation of the mitochondrial membrane potential of tigecycline-treated CML cells using JC-1
staining and flow cytometry. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was used as the positive control. (d) Reactive oxygen species (ROS) levels
in the CML cells were measured by flow cytometry. Ctrl, control; TI, tigecycline-treated cells. *P< 0.05
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in the activations of caspase-9 and the downstream
effector caspase-3, which ultimately lead to apoptosis
[17, 18]. Therefore, we used western blotting to detect
cytochrome c/caspase-9/caspase-3 protein levels pre- and
post-treatment. There were no obvious changes in cyto-
chrome c, caspase-9, and caspase-3 levels in the untreated
cells. However, exposure to tigecycline resulted in in-
creased cytochrome c levels in the cytoplasm of the
treated cells. Furthermore, in all the cell lines, we observed
that the levels of downstream sensors of cytochrome
c, cleaved caspase-9, and caspase-3 in the tigecycline-
treated cells were greater than the levels of respective
proteins in the control cells (Fig. 4b). Collectively, our
data indicate that there was a redistribution of cyto-
chrome c and activations of caspase-9 and caspase-3
in response to the pro-apoptotic effect of tigecycline
in the CML cell lines.
Tigecycline induced autophagy in the CML cells by
downregulating the AKT-mTOR signaling pathway
Recently, intense attention has been paid to the roles of
autophagy in cancer development and chemotherapy resist-
ance [19–21]. Many common anticancer drugs induce not
only apoptosis but also autophagy in cancer cells. There-
fore, we investigated whether tigecycline could induce
autophagy in the CML cells. Using transmission electron
microscopy, a standard autophagy detection method, we
found more typical double-membrane autophagosomes in
the tigecycline-treated CML cells than in the control cells
(Fig. 5a).
To confirm tigecycline-induced autophagy, we chose a
novel permeable and specific fluorescent probe for
monitoring autophagy in live cells by confocal micros-
copy. When autophagy occurs in cells, the green fluores-
cent detection reagent is incorporated into the cells.
Next, green spots which represent the autophagosome
marker LC3 distribute throughout the cytoplasm or
accumulate in the perinuclear region of the cells. The
confocal microscopy showed an appreciable increase in
green fluorescent spots either in the cytoplasm or sur-
rounding blue fluorescent nuclei in the K562, KBM5,
and KBM5-STI cells after treatment with tigecycline.
However, the untreated cells did not show an obvious
green fluorescence (Fig. 5b).
Furthermore, we investigated if there was autophagic
flux in the tigecycline-treated cells. As the well-known
and vital proteins in autophagic flux, SQSTM1 (p62)
and LC3BI/II were selected as the representative pro-
teins of autophagy in the western blotting assay. The
assay showed a decrease in p62 protein levels and an in-
crease in LC3BII protein levels in the tigecycline-treated
CML cells (Fig. 5c). Taken together, our results indicate
that tigecycline caused autophagy in the CML cell lines.
PI3K-AKT-mTOR signal pathway is activated by
several stimuli involved in cell proliferation, survival,
and metabolism, as well as autophagy. mTOR is a crit-
ical mediator in autophagy induction. When activated,
Fig. 3 Tigecycline inhibits energy metabolism in CML cells. (a) Mitochondrial respiration of the CML cells was measured before and after
treatment with tigecycline, and is represented by the oxygen consumption rate (OCR) curve and values. Oligo, oligomycin; A&R, antimycin A and
rotenone. (b) Effect of tigecycline on glycolysis in the CML cells. Glycolysis capacities of the CML cells are shown by the extracellular acidification
rate (ECAR) curves and values. Oligo, oligomycin. *P < 0.05
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mTOR (AKT and MAPK pathways) suppresses autoph-
agy; however, its negative regulation (AMPK and p53
pathways) results in the promotion of autophagy [22].
Currently, the PI3K-AKT-mTOR pathway has been an
attractive molecular target for novel anticancer therapies
in many types of cancers. It was observed that tigecyc-
line significantly inhibited this signaling pathway, as was
evidenced by inhibition of the phosphorylations of AKT
Fig. 4 Tigecycline causes apoptosis of CML cells by activating the cytochrome c/caspase-9/caspase-3 signaling pathway. (a) Apoptosis assay of
the CML cells in response to stimulation with tigecycline. Left panel: a representative flow cytometry plots for CML cells stained with annexin V-
FITC/PI-stained. Right panel: percentage apoptosis of the CML cells. Apoptosis was defined as the percentage of annexin V-positive cells. (b) West-
ern blot analyses of cytochrome c, cleaved caspase-9, and caspase-3 protein levels. Cyto.C (Mito), cytochrome c protein in the mitochondria;
Cyto.C (Cyto), cytochrome c protein in the cytoplasm. Cytochrome c oxidase-4 and β-actin were used as the reference proteins for the analyses
of mitochondrial and cytoplasmic proteins, respectively. *P < 0.05
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Fig. 5 Tigecycline induces autophagy of CML cells by downregulating the PI3K-ATK-mTOR signaling pathway. (a) Autophagic vacuoles were measured
by transmission electron microscopy. Upper panel: autophagic vacuoles in CML cells with and without tigecycline treatment. Lower panel: amplified
image of autophagic vacuoles in tigecycline-treated CML cells. (b) Confocal microscopy analysis of autophagy. Blue spots indicate nuclei stained with
4',6-diamidino-2-phenylindole (DAPI). Green spots indicate autophagic vacuoles stained with LC3B dye. (c) Western blot analysis to evaluate the levels
of autophagy related protein P62 and LC3B, and mTOR and its upstream regulator AKT, and downstream sensors P70S6 and 4E-BP1
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(Ser473 and Thr308) and mTOR (Ser2448), as well as
their downstream protein P70S6 (Thr389) and 4E-BP1
(Thr37/46) (Fig. 5c). These results indicate that tigecyc-
line can induce autophagy by inhibiting the PI3K-AKT-
mTOR signaling pathway.
Pharmacological inhibition or genetic ablation of autophagy
enhanced tigecycline-induced death of CML cells
We next sought to determine whether inhibition of au-
tophagy would interfere with the inhibitory effect of tige-
cycline. Some studies have suggested that CQ suppresses
autophagosomal fusion and degradation by inhibiting
lysosomal hydrolases, which leads to apoptosis [23, 24].
Therefore, CQ can prevent the autophagy marker LC3BII
from degrading and induce an increase in LC3BII protein
levels. Due to its inhibitory effect on autophagy, CQ was
selected as the autophagy blocker in this study. Our re-
sults showed that the protein level of LC3BII in the cells
cultured with tigecycline and CQ was markedly higher
than that in the cells treated with tigecycline or CQ alone
(Fig. 6a). This suggested that CQ significantly inhibited
tigecycline-induced autophagy. Notably, the flow cytome-
try analysis revealed that, the treatment with tigecycline
combined with CQ resulted in a strong synergetic effect
on apoptosis, which was higher than the effect of either
agent alone (Fig. 6b). Furthermore, this synergistic effect
was still observed when CQ was changed to 3-MA, which
is also an autophagy inhibitor (Fig. 6b). In order to further
investigate whether autophagy directly contributes to en-
hancing tigecycline-induced apoptosis, we used siRNA
technology to target the key autophagy molecule ATG5 to
ablate autophagy at the genetic level in the KBM5 and
KBM5 T315I cell lines. As shown in Fig. 6c, the protein
level of ATG5 in the ATG5 siRNA-transfected cells was
significantly lower than that in the cells transfected with
SCR siRNA. Moreover, tigecycline did not induce the con-
version of LC3BI to LC3BIIin the siRNA-ATG5 cells
(Fig. 6d). In the flow cytometry analysis, knockdown of
ATG5 by siRNA markedly increased cell sensitivity to the
inhibitory effect of tigecycline more than transfection with
SCR siRNA did (Fig. 6e). Taken together, these results
indicate that combining tigecycline use and autophagy
inhibition could be an effective approach in CML
treatment, especially since the synergistic effect of the two
drugs was still observed irrespective of the ABL tyrosine
kinase point mutation status of the cells.
The selective anticancer effect of tigecycline is based on
mitochondrial dependency and the metabolism type
occurring in the tumor
As previously mentioned, we inferred that tigecycline may
exert a powerful anticancer activity against CML cells,
including those with poor prognosis markers. However, it is
unknown whether tigecycline selectively targeted the CML
cells. We used bone marrow mononuclear cells from
healthy donors to study the effects of tigecycline on normal
cells. Surprisingly, tigecycline did not trigger the death of
the normal bone marrow mononuclear cells even after it
was used at a relatively high concentration (Fig. 7a). In line
with the results of the apoptosis study, tigecycline did not
increase the protein level of cleaved caspase-3 in the normal
cells (Fig. 7b). This suggests that tigecycline may be inactive
against bone marrow mononuclear cells from healthy do-
nors, which were representative of normal cells in the study.
We further studied the different effects of tigecycline
on cancer cells and normal cells by measuring the meta-
bolic characteristics of both cells using an extracellular
flux analyzer to determine live cell OCR and ECAR. In
the OCR curve, the bone marrow mononuclear cells
from both CML patients and healthy donors showed
similar levels of basal respiration; however, the maximal
and minimal respiration levels were lower in the CML
samples (Fig. 7c). On the other hand, in the glycolytic
function assay, the ECAR level in the CML cells was sig-
nificantly higher than that in the healthy cells (Fig. 7d).
When the cells were treated with the same concentra-
tion of tigecycline, only the CML cells showed signifi-
cant decreases in OCR and ECAR (Fig. 7c, d). It
suggested that the CML cells were dependent on mito-
chondrial bioenergy functions, which may be a weakness
of CML cells that tigecycline targeted.
Next, we assayed the mitochondrial characteristics of
the mononuclear cells from the healthy donors and
CML patients. Initially, there were no differences in the
basal mitochondrial membrane potentials between the
two groups of cells. In addition, there was no mitochon-
drial membrane depolarization in the normal cells even
after 48 h of treatment with tigecycline (Fig. 7e). Fur-
thermore, after using MitoTracker® Green FM dye to
stain mitochondria irrespective of the mitochondrial
membrane potential, we observed that mitochondrial
mass was higher in the CML cells than in the normal
cells (Fig. 7f ). Finally, we evaluated the mtDNA copy
number by qPCR using ND1 as the mtDNA gene and
HGB as the nuclear gene [25]. The cells obtained from
the CML patients had a significantly higher relative
mtDNA content compared to those obtained from the
normal subjects (Fig. 7g). Overall, these findings validate
that leukemic cells display a greater mitochondrial
dependence and a larger bioenergy reliance than normal
cells do. In addition, the results explain why tigecycline
shows a selective anticancer activity.
Discussion
Although the major breakthough TKIs make, the emer-
gence of drug resistance, which can occur in a mutant-
dependent or mutant-independent manner, is still is a
challenge in their use. The potential therapeutic targets
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in cases of drug resistance, which are based on differ-
ences between cancer cells and normal cells, remain to
be explored. In tumorigenesis, glycolysis is not only an
energy-production means but also a biosynthetic tool
that supports cell survival and proliferation. Mounting
evidence shows that abnormal dependence on glycolysis
during energy production in cancer cells is well co-
rrelated to therapeutic resistance in cancer treatment
[26]. It has been reported that upregulation of lactate
dehydrogenase-A, which plays a key role in the glycolytic
pathway for regulating the conversion of pyruvate to
lactate, causes resistance to paclitaxel in breast cancer
treatment [27]. Furthermore, a high expression of pyruvate
kinase M2 has been noted to contribute to resistance to 5-
fluorouracil in patients with colorectal cancer [28]. Add-
itionally, a high level of pyruvate dehydrogenase is linked to
sorafenib-acquired resistance in hepatocellular carcinoma
cells [29]. In the present study, the levels of glycolysis and
mitochondrial respiration were higher in the primary CML
cells than they were in the healthy cells. These data suggest
that the CML cells relied heavily on glycolytic and mito-
chondrial functions to meet the high demands of energy
production and metabolism and these effects were sup-
ported by an accelerated mitochondrial protein translation.
Tigecycline is a relatively new antibiotic that has a
broad antibacterial spectrum against gram-positive and
Fig. 6 Combining tigecycline use with autophagy inhibition shows synergetic cytotoxicity against CML cells. (a) Protein level of LC3B
in CML cells that were treated with tigecycline and/or chloroquine (CQ). (b) Assay of apoptosis of CMLcells exposed to tigecycline,
CQ, 3-methyladenine(3-MA), or their combination treatment. (c) ATG5 protein levels in KBM5 and KBM5-STI cells that were transiently
transfected with siATG5 and evaluated by western blotting. (d) LC3B protein levels in CML cells with and without ATG5 knockdown
were measured after treatment with tigecycline. (e) Apoptotic assay of CML cells subjected to ATG5 silence after stimulation with
tigecycline. *P < 0.05
Lu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:43 Page 11 of 14
gram-negative pathogens via binding to the 30S bacterial
ribosomal subunit. Interestingly, the 30S bacterial ribo-
some is homologous to the 28S mitochondrial ribosome
in eukaryotic cells [13]. Consequently, tigecycline acts as
a novel anticancer drug due to its inhibition of mito-
chondrial protein translation. However, whether tigecyc-
line improves drug-resistance in CML is still unknown.
Hence, we implemented a comprehensive in vitro study
to evaluate the mechanism underlying the anti-leukemic
effect of tigecycline. First, tigecycline inhibited the growths
of CML primary cells and cell lines, including imatinib-
sensitive and imatinib-resistant cells, by impairing mito-
chondrial biogenesis. In addition, tigecycline suppressed the
activities of the mitochondrial-encoded proteins Cox-1 and
Cox-2, but not the activity of the nuclear-encoded protein
Cox-4. This resulted in a downregulation of mitochondrial
Fig. 7 Tigecycline has no obvious inhibitory effect on normal cells. (a) Death of normal bone marrow mononuclear cells exposed to tigecycline in
different time points were measured by flow cytometry. (b) Western blot analysis of cleaved caspase-3 protein level in normal cells. (c) Effect of tigecycline
on the oxygen consumption rate (OCR) curves and values for CML cells and normal cells. (d) Analyses of the glycolysis capacity of leukemic and normal
cells were performed before and after stimulation with tigecycline. (e) The mitochondrial membrane potentials of leukemic and normal cells before and
after treatment with tigecycline. (f) Mitochondrial mass of normal cells and CML cells was measured by incubating the cells with MitoTracker® Green FM
dye. (g) Mitochondrial DNA (mtDNA) copy number was analyzed by QPCR. *P< 0.05
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electron transport respiratory chain and a reduction in
OCR. In addition, there was mitochondrial membrane
depolarization and low ROS production. As a byproduct of
the electron transport chain, ROS usually increase rapidly
after treatment of cells with inhibitors of the electron
transport chain, such as oligomycin, rotenone, and antimy-
cin A. We speculated that tigecycline may not inhibit
electron transport chain enzymes directly in a unique
mechanism distinct from other electron transport chain in-
hibitors do. Furthermore, tigecycline reduced the enhanced
glycolytic level (ECAR) in the CML cells and showed an in-
hibitory effect on the CML cells, including those that were
imatinib-resistant with T315I mutation. Subsequently, the
tigecycline-treated CML cells were prone to apoptosis via
activation of the cytochrome c/caspase-9/caspase-3 path-
way. Recently, Karvela and colleagues demonstrated that
knockdown of the autophagy-mediated protein ATG7 leads
to decreased glycolysis [30]. Moreover, autophagy serves as
a “weapon” for cancer cells to response to chemotherapy
and to oppose the mechanisms of apoptosis. Therefore, we
explored the role of tigecycline in autophagy in the CML
cells. We observed that tigecycline induced autophagy in
the CML cells by downregulating the PI3K-AKT-mTOR
signaling pathway. Next, combined treatment by using
tigecycline and autophagy inhibition further enhanced the
sensitivity of the CML cells to tigecycline-induced cytotox-
icity. Surprisingly, tigecycline showed no cytotoxicity to the
normal cells because of the differences in the metabolic
type and mitochondrial biogenesis between leukemic cells
and their healthy counterparts. The levels of glycolysis and
mitochondrial respiration in the primary CML cells were
higher than the respective levels in the normal cells.
Additionally, mitochondrial mass and relative mtDNA con-
tent were higher in the primary CML cells than they were
in the healthy control cells.
Due to the selective anti-leukemic activity of tigecyc-
line, the latter seems to be a promising agent for tumor
treatment. However, it has been reported that, after
monotherapy with tigecycline, no significant pharmaco-
dynamic changes or clinical responses were observed in
patients with refractory acute myeloid leukemia (AML)
[31]. This suggests that the administration route, dose,
and use of tigecycline in combination with other tr-
eatments should be explored to improve the anticancer
effect of tigecycline. In this regards, most CML patients
after combination treatment of tigecycline with pharma-
cological inhibition of autophagy may obtain efficient
treatment response, even the patients with poor prog-
nostic markers.
Conclusions
In summary, our study showed that tigecycline inhibited
the proliferation of CML primary cells and cell lines includ-
ing the drug-sensitive and drug-resistant cells. Tigecycline
suppressed mitochondrial functions and metabolism of
CML cells and resulted in cell death by via activation of
cytochrome-c/ caspase-9/ caspase-3 pathway. Furthermore,
tigecycline induced autophagy by downregulation of PI3K-
AKT-mTOR pathway and combination of tigecycline with
inhibition of autophagy could further enhance this anti-
cancer effect. Therefore, combining tigecycline use with
autophagy inhibition may be a novel approach in over-
coming drug resistance in CML treatment and this
combination therapy should be further studied.
Abbreviations
2-DG: 2-deoxyglucose; 3-MA: 3-methyladenine; A/R: Antimucin A/ rotenone;
ATG-5: Autophagy related 5; ATP: Adenosine triphosphate; CCCP: Carbonyl
cyanide 3-chlorophenylhydrazone; CCK8: Cell counting kit-8; CML: Chronic
myeloid leukemia; Cox-1: Cytochrome c oxidase-1; CQ: Chloroquine;
ECAR: Extracellular acidification rate; FCCP: Carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone; mtDNA: Mitochdrial deoxyribonucleic
acid; OCR: Oxygen consumption rate; OXPHOS: Oxidative phosphorylation;
QPCR: Quantitative polymerase chain reaction; ROS: Reactive oxygen species;
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis;
siRNA: Small interfering ribonucleic acid; TKI: Tyrosine kinase inhibitor.
Acknowledgements
We are very grateful to Prof. Michael Andreeff for the cell line KBM5-STI cells.
Funding
This work was supported by the Medical research foundation of Guangdong
province (NO. 2015124162336427) and the Science and Technology Planning
Project of Guangdong Province (2014A020211019).
Availability of data and materials
All data generated or analysed during this study are included in this
published article. Further details are available on request.
Authors’ contributions
ZL and NX designed the experiments, performed the experiments, wrote the
manuscript and analyzed the data. BH, CP, YL and HZ have contributed to
experimental work. XL and QL designed and conducted the experiments
and revised the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Medical Ethics Committee of Nanfang
Hospital (No. NFEC-2016-144) and carried out in according to the Declaration
of Helsinki. All patients and normal donors provided written informed
consent.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutionalaffiliations.
Received: 13 January 2017 Accepted: 1 March 2017
References
1. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa
staining. Nature. 1973;243(5405):290–3.
2. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic
myelogenous leukemia-specific P210 protein is the product of the bcr/abl
hybrid gene. Science. 1986;233(4760):212–4.
Lu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:43 Page 13 of 14
3. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic
myeloid leukemia. N Engl J Med. 2001;344(14):1084–6.
4. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug
resistance, and the road to a cure for chronic myeloid leukemia. Blood.
2007;110(7):2242–9.
5. Desplat V, Faucher JL, Mahon FX, Dello Sbarba P, Praloran V, Ivanovic Z.
Hypoxia modifies proliferation and differentiation of CD34(+) CML cells.
Stem Cells. 2002;20(4):347–54.
6. Hammond EM, Asselin MC, Forster D, O'Connor JP, Senra JM, Williams KJ.
The meaning, measurement and modification of hypoxia in the laboratory
and the clinic. Clin Oncol (R Coll Radiol). 2014;26(5):277–88.
7. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg
effect: the metabolic requirements of cell proliferation. Science. 2009;
324(5930):1029–33.
8. Viale A, Pettazzoni P, Lyssiotis CA, et al. Oncogene ablation-resistant
pancreatic cancer cells depend on mitochondrial function. Nature. 2014;
514(7524):628–32.
9. Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;
166(3):555–66.
10. Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control.
Nat Rev Cancer. 2005;5:886–97.
11. Klionsky DJ. Autophagy: from phenomenology to molecular understanding
in less than a decade. Nat Rev Mol Cell Biol. 2007;8:931–7.
12. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates
tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-
positive cells including primary CML stem cells. J Clin Invest. 2009;119:1109–23.
13. Lamb R, Ozsvari B, Lisanti CL, et al. Antibiotics that target mitochondria
effectively eradicate cancer stem cells, across multiple tumor types: treating
cancer like an infectious disease. Oncotarget. 2015;6(7):4569–84.
14. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of the
human mitochondrial genome. Nature. 1981;290(5806):457–65.
15. Tam EW, Feigenbaum A, Addis JB, et al. A novel mitochondrial DNA
mutation in COX1 leads to strokes, seizures, and lactic acidosis.
Neuropediatrics. 2008;39(6):328–34.
16. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death.
Science. 2004;305(5684):626–9.
17. Schägger H. Respiratory chain supercomplexes of mitochondria and
bacteria. Biochim Biophys Acta. 2002;1555(1–3):154–9.
18. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic
program in cell-free extracts: requirement for dATP and cytochrome c.
Cell. 1996;86(1):147–57.
19. Nencioni A, Cea M, Montecucco F, et al. Autophagy in blood cancers:
biological role and therapeutic implications. Haematologica. 2013;98(9):
1335–43.
20. Chi KH, Wang YS, Huang YC, et al. Simultaneous activation and inhibition of
autophagy sensitizes cancer cells to chemotherapy. Oncotarget 2016 July 28.
[Epub ahead of print].
21. Aveic S, Tonini GP. Resistance to receptor tyrosine kinase inhibitors in solid
tumors: can we improve the cancer fighting strategy by blocking
autophagy? Cancer Cell Int. 2016;16:62.
22. Alers S, Löffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the
regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol.
2012;32(1):2–11.
23. Boya P, González-Polo RA, Casares N, et al. Inhibition of macroautophagy
triggers apoptosis. Mol Cell Biol. 2005;25(3):1025–40.
24. Grimaldi A, Santini D, Zappavigna S, et al. Antagonistic effects of
chloroquine on autophagy occurrence potentiate the anticancer effects of
everolimus on renal cancer cells. Cancer Biol Ther. 2015;16(4):567–79.
25. Abu-Amero KK, Kondkar AA, Azad TA, Sultan T, Kalantan H, Al-Muammar
AM. Keratoconus is associated with increased copy number of
mitochondrial DNA. Mol Vis. 2014;20:1203–8.
26. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer
therapeutics. Cell Death Dis. 2013;4:e532.
27. Zhou M, Zhao Y, Ding Y, et al. Warburg effect in chemosensitivity: targeting
lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol.
Mol Cancer. 2010;9:33.
28. Shin YK, Yoo BC, Hong YS, et al. Upregulation of glycolytic enzymes in
proteins secreted from human colon cancer cells with 5-fluorouracil
resistance. Electrophoresis. 2009;30(12):2182–92.
29. Shen YC, Ou DL, Hsu C, et al. Activating oxidative phosphorylation by a
pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of
hepatocellular carcinoma. Br J Cancer. 2013;108(1):72–81.
30. Karvela M, Baquero P, Kuntz EM, et al. ATG7 regulates energy metabolism,
differentiation and survival of Philadelphia-chromosome-positive cells.
Autophagy. 2016;12(6):936–48.
31. Reed GA, Schiller GJ, Kambhampati S, et al. A Phase 1 study of intravenous
infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med.
2016;5(11):3031–40.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:43 Page 14 of 14
